PMID- 17192565
OWN - NLM
STAT- MEDLINE
DCOM- 20070305
LR  - 20220330
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 1088
DP  - 2006 Nov
TI  - Regulation of dendritic cell differentiation by vasoactive intestinal peptide: 
      therapeutic applications on autoimmunity and transplantation.
PG  - 187-94
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) 
      involved in the defense of the body and in the maintenance of the immune 
      tolerance. The regulation of their maturation, migration, and expression of 
      stimulatory and costimulatory molecules has major consequences on the immune 
      response. The endogenous factors that regulate DC function are poorly known. 
      Vasoactive intestinal peptide (VIP) is a neuropeptide with potent 
      anti-inflammatory actions. This anti-inflammatory profile is maintained partially 
      through effects on DC differentiation/function. Thus, VIP has differential 
      effects on DCs, depending on the differentiation and stimulatory states. Immature 
      DCs treated with VIP exhibit increased CD86 expression and induce CD4(+) T cell 
      proliferation. In addition, the CD4(+) T cells activated in vitro or in vivo by 
      VIP-treated iDCs exhibit a Th2 phenotype. In contrast, VIP reduces both CD86 and 
      CD80 expression on lipopolysaccharide (LPS)-stimulated DCs, and inhibits the 
      capacity of DCs to induce in vitro or in vivo T cell proliferation. However, 
      addition of VIP in the early states of DC differentiation results in the 
      generation of DCs that cannot mature following inflammatory stimuli that exhibit 
      a tolerogenic phenotype, characterized by low expression of costimulatory 
      molecules (CD40, CD80, and CD86), low production of proinflammatory cytokines, 
      increased production of IL-10, and capacity to induce regulatory T cells with 
      suppressive actions. The effect of VIP on the DC-Treg axis represents an 
      additional mechanism for their general anti-inflammatory role, particularly 
      relevant in autoimmunity and transplantation.
FAU - Chorny, Alejo
AU  - Chorny A
AD  - Institute of Parasitology and Biomedicine, CSIC, Granada 18100, Spain.
FAU - Gonzalez-Rey, Elena
AU  - Gonzalez-Rey E
FAU - Delgado, Mario
AU  - Delgado M
LA  - eng
GR  - 2R01A047325/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 37221-79-7 (Vasoactive Intestinal Peptide)
SB  - IM
MH  - Animals
MH  - Autoimmune Diseases/*drug therapy/immunology
MH  - Cell Differentiation/drug effects/immunology
MH  - Dendritic Cells/drug effects/*immunology
MH  - Graft Rejection/*drug therapy/immunology
MH  - Humans
MH  - Transplantation Immunology
MH  - Vasoactive Intestinal Peptide/*immunology/*therapeutic use
RF  - 20
EDAT- 2006/12/29 09:00
MHDA- 2007/03/06 09:00
CRDT- 2006/12/29 09:00
PHST- 2006/12/29 09:00 [pubmed]
PHST- 2007/03/06 09:00 [medline]
PHST- 2006/12/29 09:00 [entrez]
AID - 1088/1/187 [pii]
AID - 10.1196/annals.1366.004 [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2006 Nov;1088:187-94. doi: 10.1196/annals.1366.004.